BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16732583)

  • 21. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
    Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
    Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.
    Cohen JM; Sebire NJ; Harvey J; Gaspar HB; Cathy C; Jones A; Rao K; Cubitt D; Amrolia PJ; Davies EG; Veys P
    Blood; 2007 Sep; 110(6):2209-14. PubMed ID: 17502458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
    Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome.
    Silvana B; Antonella LM; Basilia P; Trombetta D; Saija A; Salpietro C
    Pediatr Transplant; 2007 Aug; 11(5):552-6. PubMed ID: 17631027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ; Lam MS; Rosenberg A
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
    Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
    Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for severe combined immune deficiency.
    Qasim W; Gaspar HB; Thrasher AJ
    Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphoproliferative disorders associated with congenital immunodeficiencies.
    Elenitoba-Johnson KS; Jaffe ES
    Semin Diagn Pathol; 1997 Feb; 14(1):35-47. PubMed ID: 9044508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
    Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB
    Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
    Al-Akash SI; Al Makadma AS; Al Omari MG
    Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
    Vischini G; Cudillo L; Ferrannini M; Di Daniele N; Cerretti R; Arcese W
    J Nephrol; 2009; 22(1):160-3. PubMed ID: 19229832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases.
    Zompi S; Tulliez M; Conti F; Leblond V; Gaulard P; Blanche P; Durand F; Ghandi D; Dreyfus F; Louvel A; Calmus Y; Bouscary D
    J Hepatol; 2000 Mar; 32(3):521-7. PubMed ID: 10735625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoproliferative disorder of the airway of an adolescent without immunodeficiency.
    Boesch RP; Daines M; Kaul A; Cotton R; Amin R
    Int J Pediatr Otorhinolaryngol; 2005 Nov; 69(11):1591-4. PubMed ID: 15963576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.
    Pescovitz MD
    Pediatr Transplant; 2004 Feb; 8(1):9-21. PubMed ID: 15009836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.